In developing and deploying solutions like RWD Cohort Discovery in healthcare, several concerns related to responsible AI should be addressed to ensure  **fairness, transparency, and accountability**. Below are some key ethical considerations and potential biases to be mindful of concerning the creation and use of patient cohorts based on observational health data coming from medical systems or longitudinal patient insurance claims. 

### Bias in Input Data
 **Demographic Bias** 
If the input patient data or the created cohort based on clinical criteria over-represent certain demographics (e.g., age, gender, race, or location), it can lead to biased cohort insights. For example, if data skews towards urban areas, the solution may not accurately capture the observational health outcomes in rural regions. 
  - Ensure data represents diverse patient social factors, health systems and demographics. Regularly review and audit datasets created in cohorts to detect any demographic imbalances that to lead to biased or inaccurate insights derived from real world patient data.
  
**Socioeconomic Bias:**
Data on patient populations may inadvertently favor wealthier areas or practices due to inequity in healthcare access or social imbalances around seeking care or reimbursements for care, leading to bias against those serving lower-income communities.
-  Balance datasets and evaluate patients in a cohort by including data from various economic and social factor strata and regions to ensure equitable representation.

**Data Quality and Source Bias** 
Input data may come from various sources (e.g., multiple claims, EMR systems, or syndicated data providers), each with its own biases and quality. Potentially duplicated patient records from multiple sources could also bias estimates of cohort incidence or prevalence. 
-  Consider the limitations of each data source and use techniques like data augmentation, bias correction, quality metrics, and checks to ensure the quality of possibly disparate data sources does not lead to biased patient population cohorts for further analysis

Moreover, patient cohorts created from this solution should be used to promote and prioritize unbiased and accurate insights from observational patient health signals and promote research to develop programs that improve patient outcomes and therapeutic or health access and journey as opposed to re-enforcing or deepening disparities or biases in healthcare. Further models built in real world evidence (RWE) studies should be evaluated with a rigorous, responsible AI ethics process to ensure no biases are propagated, all subpopulations are considered, the observational nature of the data is incorporated (through methods like propensity matching and causal analysis) to avoid confounding factors, and model interpretability and explainability is in place.

### Caution and Consideration of Sample Solution Data
As a reminder, the synthetic data sources used in the example application of this solution do NOT reflect in any way real distributions of patient or disease characterizations, and no insights or assumptions around observational health outcomes patterns should be made from the examples insights derived from the patient cohorts.  They should not be used in any further downstream business decision processes. 

Please refer to the [Centers for Medicare and Medicaid Services (CMS) Linkable 2008–2010 Medicare Data
Entrepreneurs’ Synthetic Public Use File (DE-SynPUF)](https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/SynPUFs/Downloads/SynPUF_DUG.pdf) for further details.
